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Abstract
Heterogeneous phenotypes of complex disorders pose a great challenge for genetic association studies and for the
development of personalized treatment strategies. Cluster analysis of phenotypic data has been recently proposed as a
reliable auxiliary method for such studies. A cohort of 236 treatment-seeking smokers was investigated after overnight
nicotine abstinence. Alpha4 nicotinic acetylcholine receptor (nAChR) subunit-related phenotypes were assessed by the
Fagerstro¨m Test for Nicotine Dependence (FTND), exhaled carbon monoxide (CO) measurements, the Minnesota Nicotine
Withdrawal Scale (MNWS) and the Zung Self-Rating Depression Scale (ZSDS). Seven tag SNPs (single-nucleotide
polymorphisms) across CHRNA4 (the gene encoding alpha4 subunit of the nicotinic acetylcholine receptor) were genotyped
and two-step cluster analysis was used for phenotypic cluster characterization. Haplotype estimation was determined by
HapStat module of R 2.0 software. Three different phenotypic clusters were identified and the C3 cluster was characterized
by the highest ZSDS and MNWS scores compared to others. Furthermore, lifetime prevalence of major depression was
significantly higher in the C3 cluster (p= 0.019). In genetic association tests, this cluster was also significantly associated with
rs3787138 genotypes (p= 0.004) while haplotype analyses of three SNPs (rs3787138, rs1044396, rs3787140) revealed that
the risk for C3 phenotype was almost three times higher in GCC haplotype carriers compared to others (pperm= 0.013). This is
the first report on a significant association between CHRNA4 variants and a subgroup of smokers characterized by massive
withdrawal symptoms and affective vulnerability. Identification of such a phenotypic cluster can be a pivotal step for further
pharmacogenetic studies on ligands of the alpha4 nAChR subunit. Our results suggest that performing cluster analysis in
genetic association studies can be proposed for complex disorders.
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Introduction
Nicotine dependence is the most prevalent psychiatric disorder
in the world and it is responsible for the highest preventable
mortality in developed countries [1,2]. The increasing body of
evidence about the molecular background of smoking behavior
suggests that genetic factors have significant role in the
pathomechanism but the picture is still not complete. One of the
most important candidate genes of smoking behavior is the gene
encoding alpha4 subunit of the nicotinic acetylcholine receptor
(CHRNA4) because among nicotinic acetylcholine receptors
(nAChRs) those containing alpha4 subunit have the highest
affinity for nicotine, the primary psychoactive component of
tobacco [3]. Moreover, the most effective pharmacological agent
for smoking cessation, varenicline is a partial agonist on
alpha4beta2 nAChRs. Despite of the evident role of CHRNA4 in
multiple smoking-related phenotypes including nicotine depen-
dence, withdrawal and affective symptoms, association studies
have provided partly inconsistent results. Positive associations
between nicotine dependence and CHRNA4 were reported in case-
control and family studies [4,5]. Nevertheless, negative findings
are also available. In a study of cigarette smokers, nicotine
dependence and serum cotinine levels were not associated with
CHRNA4 [6]. Furthermore, Spruell et al. (2012) reported that
effect of CHRNA4 was not significant on smoking cessation
outcome in a nicotine replacement therapy (NRT) treatment study
[7].
Accumulative data support that depressive phenotypes and
smoking have a multifaceted relationship (for a review, see Dome
et al. 2010 [8]) and among multiple candidate genes, CHRNA4 is
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also implicated in the development of mood disorders. Significant
associations between CHRNA4 and depression and loneliness were
demonstrated in a study of elderly population [9]. Accordingly,
negative emotionality was proved to be associated with CHRNA4
[10]. Interestingly, smoking status did not influence these
associations between CHRNA4 and affective phenotype according
to these reports [9,10].
Reconsidering the possible background of these conflicting data
on CHRNA4, we tried to find an alternative method for detecting
significant effect of CHRNA4 on smoking-related phenotypes.
Phenotypic cluster analysis is a recently proposed method for
identifying more homogenous subgroups based on parallel analysis
of co-existing phenotypic variables [11]. Furthermore, it has been
proved to be a promising method for genetic association studies of
complex diseases such as asthma and substance use disorders [12].
[13].
Since smoking is a also complex condition, our hypothesis was
that cluster analysis can be an appropriate method for finding a
subgroup displaying a more serious manifestation with potentially
greater load of genetic risk factors. To this end, we have chosen
those phenotypic variables that were proved to be linked to
CHRNA4 receptor function. Here we report for the first time a
cluster analysis of smoking-related variables and depressive
phenotype in an association study of haplotypes within CHRNA4
in smokers.
Results
Descriptive Statistics
The average number of cigarettes per day was 21.268.4, breath
CO level was 19.068.7 and FTND mean score was 6.361.2.
Mean MNWS score was 12.0166.1. Mean Zung Self-Rating
Depression scale score was 37.767.4 in the total population.
Comparing different variables between the two genders we found
that women scored significantly higher on ZSDS (35.866.5 vs.
39.468.4, p=0.006) but other factors did not differ from men.
Severe depression symptoms (above 48 points on ZSDS) were
detected in 7.5% of the sample which is significantly higher than
the Hungarian average of current episode of MDD (major
depressive disorder) [14]. A comprehensive list of the descriptive
variables is presented in Table 1.
Phenotypic Cluster Analysis
Two-step cluster analysis resulted in the strongest model when
MNWS, exhaled CO level and ZSDS score were stepped into the
model. In this model 3 different clusters were identified with
significantly differing variables (p,0.001 for all variables in
ANOVA tests). C1 was characterized by the lowest MNWS
(8.863.8) and ZSDS (34.165.1) scores and CO levels (15.063.6)
(Figure 1, Table 2). Individuals in C2 showed the highest CO
levels (30.769.3) but they scored lower on MNWS (12.064.3) and
ZSDS (37.265.7) than members of C3 (Figure 1, Table 2). The
third cluster was related to the highest MNWS (20.763.9) and
ZSDS (47.566.2) scores but exhaled CO levels were found to be
lower (16.564.6) than in C2 (Figure 1, Table 2). These results
suggest that cluster analysis revealed not only significantly different
subgroups but also identified a vulnerable subphenotype of
smokers who reacted very sensitively to acute withdrawal of
nicotine. Affective hyper-vulnerability as a crucial character of C3
is also demonstrated by the significantly higher lifetime prevalence
of MDD in the C3 group than in the others (C1=13/113,
C2= 7/48, C3=14/48, chi-square = 7.84, df = 2; p=0.019).
FTND scores and CPD (cigarettes/day) were also different among
the three subgroups identified. Both C2 and C3 had significantly
higher FTND score than of C1 (C1= 6.160.9; C2= 6.661.3;
C3= 6.761.4; pC1/C2=0.023; pC1/C3=0.009) but FTND score did
not differ between C2 and C3. In line with the highest exhaled CO
level in C2, significantly greater amount of CPD was reported in
C2 than in C1 (C1= 19.567.5; C2= 24.569.1, C3= 21.968.3;
pC1/C2=0.001). Gender distribution did not differ significantly
among the three clusters.
Single Marker Associations
We tested the effects of all SNPs on dependent variables under
five models. Single marker association tests provided three
nominally significant results: effect of rs6090378 on FTND score
(p=0.013); and effects of rs3787138 and rs3787140 on MNWS
score variance were significant but not robust enough for
Bonferroni corrections (p=0.021; p=0.026, respectively) (Table
S1). However, odds ratios for C3 phenotype were significantly
higher in G allele carriers of rs3787138 even after Bonferroni
corrections (OR=2.09 (95% CI= 1.0–4.37); p=0.004) while C
allele carriers of rs3787140 had almost double the chance to have
C3 phenotype with a nominal significance (OR=1.67 (95%
CI= 0.69–4.04); p=0.013). ZSDS, exhaled CO and CPD had no
significant relation to SNPs in single marker association models.
Haplotype Analyzes
Estimation of frequency of haploblock 1 (constructed by
rs3787138, rs1044396 and rs3787140, respectively) showed that
three haplotypes had greater than 5% frequency in the sample
(ATT=48%; ACT=38%; GCC=9%). The frequency of the
GCC haplotype was found to be the highest in the C3 cluster (chi-
square = 8.68; df = 2; p=0.013, Table 3). First we tested the effect
of haplotypes on phenotypic measurements as a continuous
variable in the total sample. HapScore test with MNWS score
resulted in a marginally significant model (pglobal=0.054). The
highest MNWS score was associated with the GCC (p=0.04) and
the lowest score with the ATT haplotypes (p=0.02; Table 4).
FTND, CPD and ZSDS total scores were not associated with
haplotypes in the total sample.
Table 1. Descriptive characteristics of the study population.
n 236
Age (years; mean6SD) 51.2612.9
Smoked cigarettes/day 21.268.4
FTND score (mean6SD) 6.361.2
CO level (ppm) (mean6SD) 19.068.7
MNWS score (mean6SD) 12.0166.1
Heavy smokers ($20 cigarettes/day) 31.8%
COPD 48.3%
First cigarette under age of 18 43.8%
ZSDS score (mean6SD) 37.767.4
ZSDS score above 48 7.5%
Smoking parents 79.7%
Anxiety disorders 10.9%
MDD 9.5%
FTND, Fagerstro¨m Test for Nicotine Dependence; MNWS, Minnesota Nicotine
Withdrawal Scale; COPD, chronic obstructive pulmonary disorder; ZSDS, Zung
Self-Rating Depression Scale; SD, standard deviation; MDD, major depressive
disorder.
doi:10.1371/journal.pone.0087141.t001
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In the next step phenotypic clusters were stepped into the model
as dependent variables. In HapScore test effect of GCC haplotype
was significantly associated with C3 (peffect=0.002) and the model
was also significant (pperm=0.018). Consequently, GLM (general
linear model) analysis revealed that odds ratio for having the C3
phenotype was almost three times higher in subjects with GCC
haplotype compared to others (OR=2.74; p=0.013; Table 5;
Figure 2).
Discussion
This is the first report demonstrating significant association
between haplotypes within CHRNA4 and phenotypic clusters of
smokers. Moreover, despite of the crucial role of alpha4 subunit in
the development of nicotine withdrawal symptoms, this is the first
study assessing the association between CHRNA4 variants and
acute nicotine withdrawal symptoms.
Our analysis identified a cluster (C3) among smokers which is
characterized by significantly more severe withdrawal symptoms
with robust affective vulnerability; not only average score on the
self-reported depression scale (ZSDS) but also lifetime prevalence
of major depression were significantly higher in this subgroup. Of
note, the size of this cluster is not negligible: about 20% of the
study population belonged to this subgroup. Genotype and
haplotype association tests showed that this special phenotype is
determined by genetic components: the chance of belonging to the
C3 phenotype group was almost three times higher in those
carrying the GCC haplotype compared to other haplotype
carriers.
The risk haplotype identified in our study has a component
described earlier as a risk allele associated with different
phenotypes in multiple studies. These findings suggest that C
allele carriers of rs1044396 (middle SNP of our haplotype) were
more prone to develop nicotine dependence [4]; they have a
higher chance to have psychological risk attitude [15] and exhibit
weaker attention functions [16]; they are more anxious and
emotionally unstable compared to T allele carriers [9,10] and
finally, T allele was found to be protective against nicotine
addiction [5]. At the same time, the effect of rs1044396 on
response to cessation promoting agents is underinvestigated yet:
the only study on this topic failed to find a positive association
between this SNP and treatment response in a heterogeneous
sample of smokers [7].
The pivotal role of rs1044396 in receptor function was
suggested by several authors. Convergent evidence hints that this
missense mutation of exon 5 in CHRNA4 yielded significant
increase in acetylcholine sensitivity which can be a reasonable
explanation for more serious withdrawal symptoms in carriers of
hypersensitive genetic variant of CHRNA4 in our sample [17,18].
Regarding the possible role of rs1044396 (also found to be a risk
SNP in our study) in receptor sensitivity, Breitling et al. proposed
that it is in tight linkage disequilibrium with the functional
rs2236196 which is associated with more than two times higher
gene expression and greater sensitivity for acute nicotine
abstinence compared to its complementary variant [4]. Apart
from addictive behaviors, crucial roles of CHRNA4 exon 5 in
emotional processes have also been confirmed [19].
From a pharmacogenetic point of view, it was demonstrated
previously that rs2236196 and also rs3787138 (an SNP which was
also found to be associated with the C3 cluster in this study) were
associated with treatment response to nicotine supplementation
therapy and/or varenicline. These results raise the possibility that
members of the C3 cluster have altered response to cessation
promoting agents which may suggest that smoking cessation
studies should not focus on smokers as a whole but rather on
phenotypically different subgroups of them [20].
Of note, exhaled CO levels were not the highest in the
genetically vulnerable cluster in our cohort. Nevertheless, this
finding is partly in line with negative results on the association
between serum cotinine levels and CHRNA4 variants [6]. Our data
confirmed previously reported results that controlling for both
cigarette experimentation and for quantity smoked during heaviest
Figure 1. Two-step cluster analysis of three phenotypic variables resulted in three significantly different clusters. Mean scores are
represented as percentages of possible maximum points for each measurements. MNWS, Minnesota Nicotine Withdrawal Scale; ZSDS, Zung Self-
Rating Depression Scale.
doi:10.1371/journal.pone.0087141.g001
Table 2. MNWS and ZSDS scores and CO levels of the three phenotypic clusters (C1, C2, C3) identified by two-step cluster analysis.
MNWS (mean±SD) ZSDS (mean±SD) CO level (mean±SD) p-value (ANOVA)
C1 (n = 110) 8.863.8 34.165.1 15.063.6 ,0.001
C2 (n = 47) 12.064.3 37.265.7 30.769.3 ,0.001
C3 (n = 44) 20.763.9 47.566.2 16.564.6 ,0.001
MNWS, Minnesota Nicotine Withdrawal Scale; ZSDS, Zung Self-Rating Depression Scale; SD, standard deviation.
doi:10.1371/journal.pone.0087141.t002
Smoking, Tobacco Withdrawal Symptoms and CHRNA4
PLOS ONE | www.plosone.org 3 January 2014 | Volume 9 | Issue 1 | e87141
period of use there are residual influences on nicotine withdrawal
(up to 23% of the total variance) [21] suggesting that there may be
genetic variance in nicotine withdrawal that is independent of
genetic effects on development of nicotine addiction [22].
In previous studies it has been demonstrated that smokers with a
history of depression report more severe withdrawal symptoms
[23–25] and have an increased risk for recurrent episodes of
depression after smoking cessation [26]. Based on our data we
suggest that this association between nicotine withdrawal and
depressive symptoms may not be valid for all smokers generally, it
is rather true for a vulnerable cluster which was found to be
associated with CHRNA4 variants.
In conclusion, we identified a clinically remarkable subgroup
within smokers characterized by salient withdrawal symptoms and
depressive signs. Here we presented a unique approach and
studied the effect of CHRNA4 haplotypes on smoking-related traits
using a special phenotypic clustering method. With the help of the
phenotypic cluster analysis the possible role of CHRNA4 in
smoking behavior and pharmacological actions of cessation agents
can be nuanced. Further pharmacological studies are required to
extend our knowledge on the role of CHRNA4 in the treatment of
nicotine dependence. Based on these findings we propose cluster
analysis combined with haplotype association test as an alternative
method for identifying genetically predisposed part of complex
disorders and for pharmacogenomic trials.
Methods
Ethics Statement
Written informed consent was obtained from all participants
and the study was approved by the the Scientific and Research
Ethics Committee of the Medical Research Council of Hungary
(ad.8-303/2009-1018EKU).
Subjects and Phenotypic Measurements
A cohort of 350 treatment-seeking smokers from 5 Hungarian
Cessation Centers was investigated in the present study. The
time between the last smoked cigarette and the clinical interview
was not a criterion for study entry, but for the current analysis
we selected only those individuals who reported an overnight
nicotine abstinence (n = 236). Participants were interviewed by a
detailed background questionnaire on smoking-related variables
such as quantity and quality of smoking, nicotine content of the
cigarette regularly smoked by them and family history of
smoking. Nicotine dependence was assessed by the Fagerstro¨m
Test for Nicotine Dependence (FTND) [27]. The 9-item version
of Minnesota Nicotine Withdrawal Scale (MNWS) was used for
detection of withdrawal symptoms [28]. The Zung Self-Rating
Depression Scale (ZSDS) was performed for estimating depres-
sive phenotype in the previous two weeks [29]. Participants
above 3 points of FTND and above 10ppm CO were included
in the study. COPD (chronic obstructive pulmonary disease) was
validated by spirometry. Clinical interviews, CO measurement
and genetic sample collection were performed by clinicians
specialized in pulmonology and smoking cessation therapy.
Genotyping, SNP Selection
Buccal mucosa samples were taken from all subjects and
7 tag SNPs (rs4522666, rs6090378, rs3787138, rs1044396,
rs3787140, rs2093107, rs755203) covering the CHRNA4 were
genotyped with Sequenom MassArray technology and the
iPLEX Gold chemistry (Sequenom Inc., San Diego, USA). In
this method allele discrimination is based on primer extension
with single mass-modified nucleotides followed by MALDI-TOF
mass spectrometry. Genotyping was performed by the Technol-
ogy Centre, Institute for Molecular Medicine Finland (FIMM),
University of Helsinki. Genotyping quality was examined by a
detailed QC procedure consisting of success rate checks,
duplicated samples and positive and negative control samples.
Genotyping was done blinded to the phenotypic data. SNPs
within CHRNA4 were selected based on literature and the
International HapMap project [4,5,10,30]. Basic characteristics
of allelic and genotype distribution were analyzed using
Haploview software 4.0 (Table S2) [31]. Minor allele frequen-
cies of each SNPs were not less than 1% in the sample and all
genotyped polymorphisms were in Hardy-Weinberg equilibrium.
Linkage disequilibrium tests showed that three SNPs (rs3787138
in intron 5, rs1044396 in exon 5 and rs3787140 in intron 2) are
in strong linkage disequilibrium (r2.95%) constructing one
Table 3. Frequencies of different haplotypes in phenotypic
clusters.
C1 C2 C3 p-value
ATT 46% 46% 38% 0.013a
ACT 41% 38% 31%
GCC 7% 7% 17%
Allelic components of the presented haplotypes are rs3787138, rs1044396 and
rs3787140 SNPs, respectively. achi-square test indicated a significantly higher
frequency of GCC haplotype in C3 compared to non-C3 clusters.
doi:10.1371/journal.pone.0087141.t003
Table 4. Haplotypic effect on MNWS score as a continuous
variable in GLM and HapScore tests.
MNWS score
GLM HapScore testa
Haplotypes Diff. 95%C.I. p-value score peffect
ATT 13.82 ref. 22.36 0.02
ACT 0.78 20.49–2.06 0.23 1.04 0.29
GCC 2.44 0.35–4.54 0.02 1.99 0.04
Allelic components of the presented haplotypes are rs3787138, rs1044396 and
rs3787140 SNPs, respectively. apmodel= 0.054; MNWS, Minnesota Nicotine
Withdrawal Scale.
doi:10.1371/journal.pone.0087141.t004
Table 5. Haplotype association tests on C3 phenotypic
cluster in GLM and HapScore tests.
GLM HapScore Testa
Haplotypes O.R. for C3 95%C.I. p-value score peffect
ATT 1.0 ref 21.24 0.21
ACT 1.02 0.62–1.78 0.98 21.02 0.32
GCC 2.74 1.23–6.09 0.013 2.71 0.002
Allelic components of the presented haplotypes are rs3787138, rs1044396 and
rs3787140 SNPs, respectively. apmodel = 0.018; GLM, general linear model.
doi:10.1371/journal.pone.0087141.t005
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haploblock (Figure 3) according to the criteria of Gabriel et al.
(2002) [32].
Statistical Methods
Two-step cluster method was used for phenotypic cluster
analysis based on Ward’s aggregation criterion performed in
SPSS 20.0 software. Smoking-related phenotypes, such as FTND
score, smoked cigarettes/day (CPD), exhaled CO level, MNWS
and ZSDS scores for depressive phenotype were stepped into the
model. The strongest model was chosen for genetic association
tests (higher than 0.5 of silhouette measure of cohesion and
segregation). Haplotype analyses were performed with GLM and
HapScore tests under additive model using HapStat modul of R
2.0 software. Rare haplotypes with a frequency less than 5% were
excluded from analyses. To avoid false positive results Bonferroni’s
correction in single marker association tests and permutation
procedures with 1000 random permutations were performed by R
2.0 software similarly to our earlier publication [33]. Permuted p-
value less than 0.05 was considered significant in haplotype
analyses. Where it was possible, models were adjusted for age and
gender (in SMA (standard major axis) and GLM tests).
Supporting Information
Table S1 Significant results of single marker association tests.
(DOCX)
Table S2 Basic characteristics of the investigated SNPs.
(DOCX)
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